Previous 10 | Next 10 |
SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a prospectus supplement with the Securitie...
Eli Lilly (LLY) has lost ~4.8% in the pre-market after the company’s full Phase 2 data for donanemab in early stage of Alzheimer's disease failed to impress the Wall Street analysts.Biogen (BIIB), the developer of much anticipated Alzheimer’s therapy, aducanumab has ad...
SHANGHAI, China and GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced...
I-MAB BioPharma is a new player in the global pharmaceuticals market with autoimmune products. It has a robust portfolio of marketable drugs with several more in the pipeline. The company has global partnerships and an international footprint that will expand drastically as its ne...
Clinical stage biopharmaceutical company I-Mab (IMAB) and Complix have signed a drug discovery deal to use Complix's proprietary Alphabody platform to deliver Cell Penetrating Alphabodies ((CPABs)) against two immuno-oncology intracellular targets.The resulting CPABs will undergo clinica...
- New Initiative is part of I-Mab’s long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology platforms to develop novel drug molecules - I-Mab continues t...
I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021 Conference Call Scheduled for March 29 at 8:00 a.m. ET with Pre-Registration Required PR Newswire SHANGHAI and GAITHERSBURG, Md. , March 3, 2021 /PRNew...
BGI Genomics of Shenzhen raised almost $300 million in a private placement for its next-gen sequencing services and genetic tests for medical institutions. New Horizon Health staged a $263 million IPO last week on the Hong Kong Exchange to support its early cancer screening tests. ...
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency PR Newswire SHANGHAI and GAITHERSBURG, Md. , Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical...
I-Mab Announces Upcoming Participation at March Conferences PR Newswire SHANGHAI and GAITHERSBURG, Md. , Feb. 24, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, developmen...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...